LuminaScanX delivers a comprehensive clinical menu across seven modality groups and monetises it through six revenue streams. The clinical breadth allows a single centre to serve a referral, a scheme member, a corporate screening programme and a hospital-outsourcing contract from the same equipment base, lifting utilisation, the central driver of imaging economics.
Clinical divisions
- General radiology — digital X-ray, contrast studies and fluoroscopy; the high-volume front door.
- Ultrasound — general, obstetric, Doppler, musculoskeletal and small-parts; the largest market segment and lowest cost per study.
- CT — brain, chest, spine, cardiac, trauma and oncology; the fastest-growing modality.
- MRI — neuro, spine, musculoskeletal, cardiac, oncology and whole-body; the highest-value studies.
- Women’s imaging — mammography, breast ultrasound and bone-density (DEXA), anchoring screening programmes.
- Cardiac imaging — CT coronary angiography, echocardiography and stress testing.
- Nuclear medicine (Phase II) — PET-CT and SPECT for oncology and specialised cardiac work.
The six revenue streams
Revenue is diversified across six streams whose blend shifts over time toward higher-value scheme and corporate work as the network matures:
|
Revenue stream |
What it is |
Y1 share |
Y5 share |
|---|---|---|---|
|
Walk-in imaging |
GP, specialist, physio and occupational referrals |
30% |
24% |
|
Medical schemes |
Discovery, Bonitas, Momentum, Fedhealth, Bestmed, GEMS |
34% |
38% |
|
Corporate health |
Executive screening, mining, aviation, insurance |
14% |
15% |
|
Hospital outsourcing |
Running imaging for day/private/rural hospitals |
8% |
11% |
|
Teleradiology |
Remote reporting for third-party sites & Africa |
9% |
8% |
|
AI services |
AI-assisted detection and triage add-ons |
5% |
4% |
StrengthUtilisation is the whole game
Imaging is a fixed-cost business: once a scanner is installed, incremental studies fall almost straight to contribution. Six demand channels feeding one asset base is the most reliable route to the high utilisation that turns EBITDA margins from 19% in Year 1 to 32% by Year 5.